| Patient | Emily Dickinson |
|---|---|
| Date of birth | 1971-12-10 |
| Identifiers | MRN HR-NI023-SYN; SSN (made up) 000-23-6081 |
| Document date | 2026-02-02 |
| Author | Lucinda Hartwell, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-week kidney and blood pressure review; nephrology consultation and kidney ultrasound on the same trip. [S]
Ms. Dickinson comes to the clinic for the first time in two years, on a quiet early appointment that combines this review, a kidney ultrasound, and her nephrology consultation so that she makes one trip. She started losartan 50 mg, atorvastatin 20 mg, and vitamin D3 three weeks ago and stopped naproxen. Her headaches are less frequent, about twice a week, and she takes acetaminophen for them. The morning nausea has eased. She has had no lightheadedness, cough, or muscle aches. Her home blood pressure averages 150/90 on her own upper-arm cuff, which read within 4 mmHg of the clinic device today. She has cut down on salted foods. She saw Dr. Adeyemi of nephrology this morning after the ultrasound. [S]
| Element | Detail |
|---|---|
| Headaches | About twice a week, down from most days; acetaminophen helps; no naproxen |
| Medication tolerance | No lightheadedness, cough, or muscle aches |
| Home blood pressure | Average 150/90 mmHg; her cuff agrees with the clinic device |
| Diet | Less salted and processed food |
| Access | One combined clinic trip for review, ultrasound, and nephrology |
| System | Result | Finding |
|---|---|---|
| Neurological | Positive | Headaches about twice a week, milder; no visual change or weakness |
| Gastrointestinal | Negative | Morning nausea eased; no vomiting |
| Cardiovascular | Negative | No chest pain, palpitations, or ankle swelling |
| Musculoskeletal | Negative | No muscle aches on atorvastatin |
| Genitourinary | Negative | No blood in the urine, frothy urine, or urinary symptoms |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naproxen sodium 220 mg oral tablet, two tablets by mouth as needed for headache (over the counter) | Two tablets as needed, up to twice a day | Oral route | 2025-10-01 to 2026-01-12 | stopped | S |
| Losartan 50 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-12 to 2026-02-02 | completed | S |
| Losartan 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-02-02 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-12 | active | S |
| Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-12 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day | Two tablets every 6 hours as needed; maximum 6 tablets a day | Oral route | 2026-01-12 | active | S |
| Dapagliflozin 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-02-02 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-02 | Body height | 163 | cm | S |
| 2026-02-02 | Body weight | 53.8 | kg | S |
| 2026-02-02 | Body mass index (BMI) [Ratio] | 20.2 | kg/m2 | S |
| 2026-02-02 | Systolic blood pressure | 148 | mm[Hg] | S |
| 2026-02-02 | Diastolic blood pressure | 88 | mm[Hg] | S |
| 2026-02-02 | Heart rate | 74 | /min | S |
| 2026-02-02 | Respiratory rate | 14 | /min | S |
| 2026-02-02 | Body temperature | 36.5 | Cel | S |
| 2026-02-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-02 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-02-02 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-02-02 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 24 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-02-02 | Urea nitrogen [Mass/volume] in Serum or Plasma | 22 | mg/dL | 6-21 mg/dL | High | S |
| 2026-02-02 | Creatinine [Mass/volume] in Serum or Plasma | 1.26 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 2026-02-02 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 51 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-02-02 | Glucose [Mass/volume] in Serum or Plasma | 90 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-02-02 | Albumin/Creatinine [Mass Ratio] in Urine | 262 | mg/g | <=30 mg/g | High | S |
Vital signs recorded on 2026-02-02; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Slight, composed, and a little tired after the trip; asked to wait in a quiet side room rather than the waiting area |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Abdomen | Soft; no renal bruit |
| Mental status | Alert and precise; mood "better"; reactive affect |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic kidney disease stage G3a A2, attributed to hypertension; synthetic modern diagnosis linked to the Bright's disease entered on her death certificate | active | confirmed | N18.31 | S — Synthetic modern diagnosis. Bright's disease as her recorded cause of death is documented (D); what it meant in her case is a retrospective question (R), and no kidney test from her lifetime exists. |
| Hypertension with chronic kidney disease (hypertensive chronic kidney disease, stage 3a); synthetic modern diagnosis linked to the retrospective view that she had severe hypertension | active | confirmed | I12.9 | S — Synthetic modern diagnosis; severe hypertension is a retrospective interpretation (R, possible), and no blood pressure from her lifetime exists. |
| Vitamin D deficiency with a mildly raised PTH in chronic kidney disease | active | confirmed | E55.9 | S — Synthetic laboratory finding at the intake visit. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Potassium and creatinine after starting an ARB | 2 to 4 weeks after starting or increasing an ACE inhibitor, ARB, SGLT2 inhibitor, or MRA | Completed today | Potassium 4.6 mmol/L, creatinine 1.26 mg/dL, eGFR 51, three weeks after starting losartan |
| Laboratory | Urine albumin-creatinine ratio, confirmatory | Repeat to confirm albuminuria at diagnosis; then with each eGFR draw | Completed today | 262 mg/g, confirming A2 (240 mg/g at intake) |
| Imaging | Kidney ultrasound | At diagnosis when the cause is uncertain; no routine surveillance imaging | Completed today | Normal-sized kidneys, mildly echogenic; no obstruction, stones, or cysts |
| Referral | Nephrology consultation | At diagnosis of albuminuric chronic kidney disease in a younger adult; or when KFRE or eGFR thresholds are met | Completed today | Seen today; agrees with hypertensive kidney disease and advises dapagliflozin and a maximum-dose ARB |
| Examination | Standardized office and home blood pressure | Every visit | Completed today | 148/88 mmHg in the clinic after five minutes' rest, average of two readings; home average 150/90 |
| Examination | Weight and cardiac auscultation | Every visit | Completed today | 53.8 kg; regular rhythm, no murmur |
| Medication safety | Medication review: NSAID avoidance and dose adjustment | Every visit | Completed today | No naproxen since intake; acetaminophen twice a week; doses suit eGFR 51 |
| Medication safety | Statin tolerance | At each review after starting | Completed today | No muscle aches on atorvastatin 20 mg |
| Laboratory | Calcium, phosphate, PTH, and 25-hydroxyvitamin D | Baseline at G3a, then every 6 to 12 months | Up to date | Baseline at intake: PTH 74 pg/mL and vitamin D 21 ng/mL; on vitamin D3; recheck at six to twelve months |
| Laboratory | Hemoglobin | At least yearly in G3 | Up to date | 12.3 g/dL at intake |
| Survey | KFRE 2- and 5-year risk | Yearly in G3 to G5 | Up to date | 0.5 and 1.6 percent at intake, below referral thresholds |
| Survey | PHQ-9 | Yearly with hypertension; repeat if symptoms change | Up to date | 6 at intake, mostly from tiredness and poor sleep with headaches |
| Self-management | Sodium, home blood pressure, and sick-day rules | Every visit | Completed today | Less salted food; weekly home readings; sick-day rules explained verbally |
Goal progress:
Guideline basis: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2017); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026)
Follow-up: Video visit in four weeks with home vital signs and home blood tests for potassium and creatinine. Next scheduled visit 2026-03-02: video visit four weeks after the losartan increase and dapagliflozin start, with home vital signs and home blood tests. [S]